Indo-European Consortium for Next Generation Influenza Vaccine Innovation

Informazioni relative al progetto

INCENTIVE

ID dell’accordo di sovvenzione: 874866

DOI

10.3030/874866

Progetto chiuso

Data della firma CE 13 Dicembre 2019

Data di avvio 1 Agosto 2020

Data di completamento 31 Gennaio 2026

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 19 965 992,50

Contributo UE

€ 9 974 293,75

Coordinato da

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH
Germany

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (4)

INCENTIVE-QIV-1,2,3 (EU) and QIV-1 (India): Study results posted in the study registry

Safety and preliminary immunogenicity results posted on the study registry. Timelines if/when final posting of results is scheduled after end of funding period will be included.

INCENTIVE-QIV: Registration of the clinical trial in the trial registry

Study registered at a WHO or ICMJapproved registry

Development and annual update of INCENTIVE dissemination and exploitation plan delivered

Plan and annual update on dissemination activities and IP exploitation.

A blueprint for rolling out stratified influenza vaccination programs, in order to optimize / maximize efficiency and effectiveness taking into account acceptability, affordability and accessibility issues

Development of blueprint for the rollout of stratified influenza vaccination program.

Websites, patent fillings, videos etc. (1)

Project presentation prepared, website launched and communication plan developed

Setting up consortium website public and secured intranet Communication plan regulating the consortium communication

Pubblicazioni

Peer reviewed articles (14)

Human Organotypic Airway and Lung Organoid Cells of Bronchiolar and Alveolar Differentiation Are Permissive to Infection by Influenza and SARS-CoV-2 Respiratory Virus

Autori: Camilla Tvedt Ekanger, Fan Zhou, Dana Bohan, Maria Lie Lotsberg, Maria Ramnefjell, Laurence Hoareau, Gro Vatne Røsland, Ning Lu, Marianne Aanerud, Fabian Gärtner, Pirjo Riitta Salminen, Mariann Bent
Pubblicato in: Frontiers in Cellular and Infection Microbiology, Numero 12, 2022, Pagina/e 841447, ISSN 2235-2988
Editore: Frontiers Media S. A.
DOI: 10.3389/fcimb.2022.841447

Seasonal influenza vaccination expands hemagglutinin-specific antibody breadth to older and future A/H3N2 viruses

Autori: Nina Urke Ertesvåg, Rebecca Jane Cox, Sarah Larteley Lartey, Kristin G-I Mohn, Karl Albert Brokstad, Mai-Chi Trieu
Pubblicato in: npj Vaccines, Numero 7, 2022, Pagina/e 490, ISSN 2059-0105
Editore: Springer Science and Business Media LLC
DOI: 10.1038/s41541-022-00490-0

Intranasal administration of octavalent next-generation influenza vaccine elicits protective immune responses against seasonal and pre-pandemic viruses

Autori: Naoko Uno, Thomas Ebensen, Carlos A. Guzman, Ted M. Ross
Pubblicato in: Journal of Virology, Numero 98, 2024, ISSN 0022-538X
Editore: American Society for Microbiology
DOI: 10.1128/jvi.00354-24

Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers

Autori: Mai-Chi Trieu, Amit Bansal, Marianne Sævik, Sonja Ljostveit, Åsne Jul-Larsen, Rebecca Jane Cox
Pubblicato in: npj Vaccines, Numero 10, 2025, Pagina/e 1259, ISSN 2059-0105
Editore: Springer Science and Business Media LLC
DOI: 10.1038/s41541-025-01259-x

Influenza hemagglutinin and neuraminidase multivalent vaccine elicits broader protective immune responses compared to vaccine formulations composed of hemagglutinin or neuraminidase

Autori: Naoko Uno, Ted M. Ross
Pubblicato in: Human Vaccines & Immunotherapeutics, Numero 21, 2026, Pagina/e 259961, ISSN 2164-5515
Editore: Landes Bioscience
DOI: 10.1080/21645515.2025.2599611

Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers

Autori: Lena Hansen, Fan Zhou, Håkon Amdam, Mai-Chi Trieu, Rebecca Jane Cox
Pubblicato in: Frontiers in Immunology, Numero 12, 2021, Pagina/e 748264, ISSN 1664-3224
Editore: Frontiers Media SA
DOI: 10.3389/fimmu.2021.748264

Impact of Pre-Existing Immunity and Age on Antibody Responses to Live Attenuated Influenza Vaccine

Autori: Lukas Hoen, Sarah Lartey, Fan Zhou, Rishi D. Pathirana, Florian Krammer, Kristin G -I Mohn, Rebecca J. Cox, Karl A. Brokstad
Pubblicato in: Vaccines, Numero 12, 2025, Pagina/e 864, ISSN 2076-393X
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines12080864

Matrix M Adjuvanted H5N1 Vaccine Elicits Broadly Neutralizing Antibodies and Neuraminidase Inhibiting Antibodies in Humans That Correlate With In Vivo Protection

Autori: Fan Zhou, Lena Hansen, Gabriel Pedersen, Gunnveig Grødeland, Rebecca Cox
Pubblicato in: Frontiers in Immunology, Numero 12, 2021, Pagina/e 747774, ISSN 1664-3224
Editore: Frontiers Media SA
DOI: 10.3389/fimmu.2021.747774

Next Generation Influenza Vaccines: Looking into theCrystal Ball

Autori: Carlos Alberto Guzmán
Pubblicato in: Vaccines, 2020, ISSN 2076-393X
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030464

DNA vaccines targeting hemagglutinin from 18 subtypes of influenza A virus to antigen-presenting cells confer broad protection

Autori: Ane Marie Anderson, Elias Tjärnhage, Daniëla Maria Hinke, Ranveig Braathen, Gunnveig Grodeland, Bjarne Bogen
Pubblicato in: Molecular Therapy Nucleic Acids, Numero 37, 2026, Pagina/e 102814, ISSN 2162-2531
Editore: Nature Publishing Group
DOI: 10.1016/j.omtn.2025.102814

Point-of-Care Influenza Testing Impacts Clinical Decision, Patient Flow, and Length of Stay in Hospitalized Adults

Autori: Elisabeth B Fjelltveit, Rebecca J Cox, Jørgen Østensjø, Bjørn Blomberg, Marit H Ebbesen, Nina Langeland, Kristin G I Mohn
Pubblicato in: The Journal of Infectious Diseases, Numero 226, 2022, Pagina/e 97-108, ISSN 0022-1899
Editore: University of Chicago Press
DOI: 10.1093/infdis/jiaa690

Safety, Immunogenicity, Efficacy and Effectiveness of Inactivated Influenza Vaccines in Healthy Pregnant Women and Children Under 5 Years: An Evidence-Based Clinical Review

Autori: Amit Bansal, Mai-Chi Trieu, Kristin G. I. Mohn, Rebecca Jane Cox
Pubblicato in: Frontiers in Immunology, Numero 12, 2021, Pagina/e 744774, ISSN 1664-3224
Editore: Frontiers Media SA
DOI: 10.3389/fimmu.2021.744774

Multivalent next generation influenza virus vaccines protect against seasonal and pre-pandemic viruses

Autori: Naoko Uno, Ted M. Ross
Pubblicato in: Scientific Reports, Numero 14, 2024, ISSN 2045-2322
Editore: Nature Publishing Group
DOI: 10.1038/s41598-023-51024-0

Prospects and Challenges in the Development of Universal Influenza Vaccines

Autori: Anders Madsen, Rebecca Jane Cox
Pubblicato in: Vaccines, Numero 8, 2025, Pagina/e 361, ISSN 2076-393X
Editore: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/vaccines8030361